WCNDD and Ono Pharmaceutical Publish Key TREK Channel Study
A new publication from the long-standing collaboration between WCNDD and Ono Pharmaceutical highlights a best-in-class in vivo tool compound targeting TREK ion channels. This study provides the first proof-of-concept for TREK activators as non-opioid analgesics and TREK inhibitors as pro-cognitive agents. Now featured among the most read in ACS Medicinal Chemistry Letters, the work marks a significant milestone in the partnership’s 12-year effort to advance novel CNS therapeutics.
đź“„ Read the publication